CINGW
MaterialsCingulate Inc - Warrants (03/12/2026)
Live · NASDAQ · May 9, Close
What's Moving CINGW Today?
No stock-specific AI insight has been generated for CINGW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.02
Fundamentals
Trading
CINGW News
20 articles- Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold ForeverYahoo Finance·Apr 24, 2026
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25Yahoo Finance·Apr 6, 2026
- CING: Laying the Foundation for 1H:27 LaunchYahoo Finance·Mar 20, 2026
- Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsYahoo Finance·Mar 18, 2026
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 13, 2025
- Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301Yahoo Finance·Nov 10, 2025
- Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom ControlYahoo Finance·Oct 28, 2025
- Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual MeetingYahoo Finance·Oct 23, 2025
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA DateYahoo Finance·Oct 14, 2025
- Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD TreatmentYahoo Finance·Sep 17, 2025
- CING: NDA SubmittedYahoo Finance·Aug 25, 2025
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25Yahoo Finance·Aug 21, 2025
- Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent HighlightsYahoo Finance·Aug 19, 2025
- Cingulate Provides Management Team UpdateYahoo Finance·Aug 15, 2025
- Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301Yahoo Finance·Aug 6, 2025
- Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301Yahoo Finance·Jul 29, 2025
- Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug ApplicationYahoo Finance·Jul 9, 2025
- Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)Yahoo Finance·Jun 18, 2025
- Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHDYahoo Finance·May 20, 2025
- CING: First Quarter 2025 ResultsYahoo Finance·May 15, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.02
Fundamentals
Trading
About Cingulate Inc - Warrants (03/12/2026)
Cingulate Inc. Warrants represent a unique investment vehicle linked to a biopharmaceutical firm dedicated to pioneering innovative therapies for Attention Deficit Hyperactivity Disorder (ADHD) and associated disorders. The company is advancing a promising lead product designed to enhance treatment efficacy and tolerability, strategically addressing significant unmet needs in a burgeoning market. With a solid pipeline and well-defined growth initiatives, Cingulate demonstrates substantial potential for delivering attractive returns, positioning itself as an appealing choice for institutional investors seeking to diversify within the healthcare landscape.